Background. The prognosis of Infective endocarditis (IE) is poor, and we conducted this investigation to evaluate the worth of admission lymphocyte-to-white blood cell ratio (LWR) for prediction of short-term outcome in IE patients. Methods. We retrospectively assessed the medical records of 147 IE patients from January 2017 to December 2019. Patients were divided into the survivor group and nonsurvivor group. Univariate and multivariate analyses were applied to estimate the independent factors contribution to in-hospital death, and receiver-operator characteristic (ROC) curve was utilized to check the performance. Results. The levels of LWR (0.17 ± 0.08 vs. 0.10 ± 0.06) were significantly increased among the survivor group compared with the nonsurvivor group ( P = 0.001). Multivariate analysis displayed that LWR (hazard ratio (HR): 1.755, 1.304–2.362, P < 0.001) was not interfered by other confounding factors for early death. Moreover, ROC analysis suggested that LWR (cutoff value = 0.10) performed the best among assessed indexes for the forecast of primary outcome (area under curve (AUC) = 0.750, 95% confidence interval (CI) = 0.634–0.867, P < 0.001, sensitivity = 70.0%, specificity = 76.4%), and the proportion of in-hospital mortality was remarkably inferior in patients with LWR > 0.10 than in those with LWR ≤ 0.10. (5.83% vs. 31.8%, P < 0.001). Conclusions. LMR is an independent, simple, universal, inexpensive, and reliable prognostic parameter to identify high-risk IE patients for in-hospital mortality.
Objective Our aim was to study the use of prostatic exosomal protein (PSEP) and prostate-specific antigen (PSA) in diagnosis of prostate-related diseases. Methods A total of 54 cases of acute prostatitis (AP), 72 cases of chronic prostatitis (CP), and 36 cases of prostate cancer (PCa) were enrolled. Levels of PSEP and PSA were analyzed. Results The positive rate and level of PSEP in CP was highest (both P < .05). The total PSA (tPSA) level in PCa was the highest (P < .05), followed by AP and CP. The free PSA (fPSA) level was lowest in CP (P < .05); fPSA/tPSA in AP was the highest (P < .05). The PSEP level in type II CP was higher than in type IIIa and type IIIb (both P < .05), and it was higher in type IIIa than in type IIIb (P < .05). The tPSA level in type IIIb was the lowest in the 3 types (both P < .05). The fPSA/tPSA in type IIIb was the highest in the 3 types (P < .05). Conclusion The PSEP combined with PSA better distinguishes prostate-related diseases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.